On Friday, Voyager Therapeutics Inc (NASDAQ: VYGR) opened higher 18.69% from the last session, before settling in for the closing price of $5.78. Price fluctuations for VYGR have ranged from $5.19 to $11.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 355.29% over the past five years. Company’s average yearly earnings per share was noted -131.55% at the time writing. With a float of $45.16 million, this company’s outstanding shares have now reached $54.63 million.
Let’s look at the performance matrix of the company that is accounted for 162 employees. In terms of profitability, gross margin is 77.42%, operating margin of 5.54%, and the pretax margin is 16.35%.
Voyager Therapeutics Inc (VYGR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Voyager Therapeutics Inc is 17.32%, while institutional ownership is 64.66%. The most recent insider transaction that took place on Oct 02 ’24, was worth 34,914. In this transaction Chief Legal Officer of this company sold 5,999 shares at a rate of $5.82, taking the stock ownership to the 86,001 shares. Before that another transaction happened on Oct 02 ’24, when Company’s Officer proposed sale 5,999 for $5.82, making the entire transaction worth $34,920.
Voyager Therapeutics Inc (VYGR) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 1.25 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.16) by 1.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -131.55% per share during the next fiscal year.
Voyager Therapeutics Inc (NASDAQ: VYGR) Trading Performance Indicators
Check out the current performance indicators for Voyager Therapeutics Inc (VYGR). In the past quarter, the stock posted a quick ratio of 8.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.72, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.57 in one year’s time.
Technical Analysis of Voyager Therapeutics Inc (VYGR)
Voyager Therapeutics Inc (NASDAQ: VYGR) saw its 5-day average volume 0.47 million, a negative change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 71.23%. Additionally, its Average True Range was 0.45.
During the past 100 days, Voyager Therapeutics Inc’s (VYGR) raw stochastic average was set at 38.30%, which indicates a significant decrease from 74.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.87% in the past 14 days, which was higher than the 78.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.52, while its 200-day Moving Average is $7.73. Nevertheless, the first resistance level for the watch stands at $7.17 in the near term. At $7.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.94. If the price goes on to break the first support level at $6.41, it is likely to go to the next support level at $5.95. The third support level lies at $5.64 if the price breaches the second support level.
Voyager Therapeutics Inc (NASDAQ: VYGR) Key Stats
There are currently 54,626K shares outstanding in the company with a market cap of 444.75 million. Presently, the company’s annual sales total 250,010 K according to its annual income of 132,330 K. Last quarter, the company’s sales amounted to 24,630 K and its income totaled -9,040 K.
